Aspen Grove Capital’s Bristol-Myers Squibb BMY Stock Holding History

Aspen Grove Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,205	Closed	-$461K	–	180
2023 Q2	$461K	Sell	7,205 -703	-9%	-$47.1K	0.15%	119
2023 Q1	$548K	Buy	7,908 +34	+0.4%	+$2.4K	0.24%	86
2022 Q4	$567K	Buy	+7,874	New	+$594K	0.26%	73

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Aspen Grove Capital's BMY Position: Q3 2023 in Review

Aspen Grove Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 7,205 shares — an estimated $461K sold.

Aspen Grove Capital first reported a position in BMY in Q4 2022 and held it in 3 quarters. The position peaked at $567K in Q4 2022. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Aspen Grove Capital reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
Aspen Grove Capital sold 7,205 Bristol-Myers Squibb shares in Q3 2023, an estimated $461K.
Aspen Grove Capital first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 3 quarters.
Aspen Grove Capital's Bristol-Myers Squibb position peaked at $567K in Q4 2022.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Aspen Grove Capital's 13F filing for Q3 2023, filed 13 Nov 2023.